Drug Makers, Hospitals Clash On Potential Changes To 340B

Drug makers are asking HHS to change the 340B drug discount program's patient definition and consider limits on contract pharmacies and off-campus sites, but hospitals are urging HHS not to narrow the patient definition and to remove or loosen the restrictions on 340B hospitals' participation in group purchasing organizations. HHS blamed the 340B drug discount in part for high drug prices and asked for feedback on how the program's growth affects prices in Medicare and in the commercial market. "While...